Propanc Biopharma, Inc.

Latest News

Aug 21, 2019

Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP

MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer,…

View All Press Releases

Aug 12, 2019

CORRECTING and REPLACING Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes

Aug 8, 2019

Propanc Biopharma Completes Development of Bio-analytical Assay Method to Quantify PRP’s Active Ingredients in Preparation for First-In-Human Study

Jul 15, 2019

Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split
Latest Publication Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting View All Publications
Antitumour efficacy of chymotrypsinogen and trypsinogen
In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation
A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer